Anticorps recombinant B2R - Anticorps primaire, specific to B2R

Cat. No.: Ab090383

GRADE & PURITY Recombinant, ExactAb™, Validated, See COA

Application

WB

Host species

Lapin

Reactive species

Humain, Souris

Isotype

Rabbit IgG

Conjugation

Unconjugated

Vue d’ensemble

L'anticorps de lapin anti-B2R humain, recombinant, peut être utilisé pour les tests de laboratoire, etc.

Specifications

Product Name

Anticorps recombinant B2R - Anticorps primaire, specific to B2R

Synonymes

Anticorps B2 | Récepteur de bradykinine B2 Anticorps B2BKR | Anticorps B2BRA | Anticorps B2R | Anticorps BDKR B2 | Anticorps BDKRB 2 | Anticorps BDKRB2 | Anticorps BK 2 | Récepteur BK 2 | Anticorps BK R2 | Récepteur BK-2 | Anticorps BK2 | Anticorps BK2

Spécifications et pureté

Recombinant, ExactAb™, validé, voir COA

Mécanismes biochimiques et physiologiques

Récepteur de la bradykinine. Il est associé à des protéines G qui activent un système de second messager phosphatidylinositol-calcium.

Espèce hôte

Lapin

Spécificité

B2R

Immunogène

A synthetic peptide derived from human B2R (AA 302-391).

Contrôle positif

WB: HUVEC and A549 cell lysates.

Conjugation

Unconjugated

Grade

ExactAb™, Recombinant, Validated

Type de chaîne lumineuse

kappa

SDS-PAGE

150 kDa

Méthode de purification

Protein A purified

Concentration

See COA

Product Line

biological_products

Stockage et expédition

Forme

Liquide

Conditions de stockage de stockage

Conserver à -20°C, éviter les congélations et décongélations répétées

Expédié en

Glacière + blocs de glace

Stabilité et stockage

Stocker à 4℃ à court terme (1-2 semaines). Conserver à -20℃ à long terme (24 mois). Dès réception, il est recommandé d'aliquoter. Éviter les cycles de congélation/décongélation.

Images

Western Blot: Recombinant B2R Antibody (Ab090383)

Recombinant B2R Antibody (Ab090383) - Western Blot
All lanes: Recombinant B2R Antibody (Ab090383) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 44 kDa
Observed band size: 82 kDa
Exposure time: 2.8 s

Application

Application

Dilution info

WB

1/1000-1/2000

Cibles associées (humaines)

BDKRB2 Tclin B2 bradykinin receptor (0 Activities)

Discover Target: BDKRB2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mécanismes d'action

Application Protocols

Item-specific validated applications, recommended dilutions, positive control samples, and protocol steps: Not specified for this item; refer to CoA/Spec Sheet.

General advice

• Until item-specific parameters are available, establish performance by a small pilot titration and include appropriate positive/negative controls. Document any optimized steps for internal reproducibility.

Biological Roles

Target context (literature; general background on B2R/BDKRB2)

• Bradykinin B2 receptor (B2R; gene BDKRB2) is a class A G protein–coupled receptor (GPCR) ubiquitously expressed in many tissues. It is constitutively present (non-inducible isoform) and binds bradykinin and related kinins with high affinity.
• Signaling: Canonically couples to Gq/11, activating phospholipase Cβ, IP3/DAG signaling, intracellular Ca2+ mobilization, and downstream kinases. Can also engage Gi and β-arrestin pathways depending on context and ligand bias (literature).
• Regulation: Receptor desensitization and internalization occur via GRK phosphorylation and β-arrestin recruitment; receptor recycling/degradation dynamics are cell-type dependent.
• Functional networks: Crosstalk with nitric oxide production, prostaglandin pathways, and other GPCRs has been documented. Dimerization/oligomerization with other receptors has been proposed in literature.

Relevance for research use (non-clinical)

• Expression profiling: Antibody-based detection enables assessment of B2R abundance and cellular localization in cell lines and tissues, and supports studies of GPCR trafficking/endocytosis.
• Pathway interrogation: Combining B2R detection with phospho-signaling readouts or Ca2+ imaging clarifies signaling competence and ligand bias.

Item-specific caveat

• This SKU’s epitope, species reactivity, and validated applications are not specified. Researchers should consult the CoA/Spec Sheet and verify specificity using appropriate positive/negative controls (e.g., BDKRB2 knockout cells, peptide blocking where applicable).

Buffer Applications

Applicability

• As an antibody reagent, performance depends on appropriate assay and storage buffers. No item-specific buffer composition or pH is provided; consult the CoA/Spec Sheet.

Assay buffer guidance (general)

• Blocking buffers: 3–5% BSA, casein, or fish gelatin in PBS/TBS to minimize nonspecific binding. Add 0.05% Tween-20 for WB/ELISA wash buffers.
• Incubation buffers: Antibody diluent matching the blocking buffer often reduces background; include carrier protein only if compatible with the assay.
• IHC/ICC: For membrane GPCR epitopes, optimize fixation (e.g., paraformaldehyde vs glyoxal), permeabilization (saponin vs Triton X-100), and antigen retrieval (citrate pH 6.0 or Tris-EDTA pH 9.0) empirically.
• Flow cytometry: Use protein-containing staining buffer (PBS + 1–2% BSA + 0.1% NaN3 if permitted) at 4°C to preserve surface epitopes; avoid azide with live cells or when using HRP.

Storage buffer considerations (general)

• Stabilizers like 10–50% glycerol and sugars (trehalose/sucrose) can improve freeze–thaw tolerance; presence/amount for this item is not specified.
• Preservatives: 0.02–0.05% sodium azide is common for long-term aqueous storage but is incompatible with peroxidase conjugates and certain downstream uses.

Note

• Prepare buffers with high-purity reagents, filter-sterilize (0.22 μm), and record lot numbers for reproducibility. Validate that buffer components do not disrupt GPCR epitopes relevant to B2R detection.

Green Alternatives

Antibody reagents are aqueous biological products; greener practice focuses on buffer selection, waste minimization, and energy-aware storage rather than replacing the reagent itself.

Greener practices (general)

• Solvent stewardship: Use water-based buffers (PBS/TBS) and avoid unnecessary organic solvent steps. Replace methanol-based fixation with glyoxal- or ethanol-based methods where compatible with epitope preservation (validate first).
• Detergent choices: Prefer readily biodegradable detergents (e.g., polysorbates) at the lowest effective concentration.
• Preservatives: If bioburden control is required, select lower-toxicity options and minimize concentrations per institutional policy (item-specific preservative content is not specified).
• Energy use: Consolidate -20°C storage to well-managed freezers; avoid frequent door openings. Aliquot to reduce freeze–thaw and waste.
• Plastic reduction: Employ reusable staining chambers and low-binding, recyclable plastics where validated for protein recovery.

Comparison examples (literature; balance of tradeoffs)

• Methanol vs glyoxal fixation: Glyoxal can reduce toxicity and VOC emissions but may alter epitope accessibility—requires re-optimization.
• DMSO cryoprotection vs trehalose/sucrose stabilization: Sugars can stabilize proteins during freezing with lower toxicity but may not fully replace DMSO in cell-based workflows.

Item-specific note

• No alternative formulation or greener substitute is specified for this product; improvements should target the surrounding workflow and consumables.

Pharmaceutical Uses

Scope

• This product is labeled for research use only. It is not intended for human or veterinary use, diagnostic procedures, or as an active pharmaceutical ingredient.

Relevant non-clinical/industrial contexts (general)

• Analytical reagent: Employed as a reference binding reagent in discovery biology, target validation, and QC assays for expression systems.
• Bioprocess development: Potential use as a capture/detection reagent in ligand-binding assays, flow cytometry for cell line development, or immunoassays monitoring B2R expression in engineered cells.
• Companion materials: May support high-content imaging or immunoassays during screening of small molecules or biologics that modulate GPCR pathways (no claims about therapeutic utility).
• Documentation: If the antibody is used in regulated environments (e.g., GLP research), obtain and archive batch-specific CoA, SDS, and any available characterization reports.

Item-specific note

• No pharmacopeial monograph, formulation role, or excipient status is provided for this item. Any use beyond basic research requires independent qualification and risk assessment by the end user.

Physical Properties

Item-specific data

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Concentration, buffer composition, pH: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item (antibodies are polydisperse biopolymers); refer to CoA/Spec Sheet.

General/literature properties for recombinant IgG-class antibodies (for context only)

• Approximate molecular mass: ~150 kDa for full-length IgG; Fab ~50 kDa; scFv ~25–30 kDa. Actual value depends on format/isotype.
• Physical state: Supplied as aqueous solution or lyophilized solid; solubility is high in aqueous buffers (PBS, TBS) and poor in organic solvents.
• Isoelectric point (pI): Typically ~6–9 depending on isotype/sequence and glycosylation.
• Stability: Enhanced at neutral to slightly basic pH with stabilizers (e.g., carrier proteins, sugars); freeze–thaw cycles can induce aggregation.
• Light/temperature sensitivity: Prolonged exposure to elevated temperature or UV can denature proteins.

Practical notes

• Avoid strong organic solvents, extremes of pH, oxidants, and surfactant-free freeze–thawing.
• If lyophilized, reconstitution in the specified buffer at the stated concentration is recommended (details not provided for this item). Always consult the item’s CoA/Spec Sheet for definitive properties.

Quality and Grades

Item-specific quality notes

• Grade/Purity: Recombinant, ExactAb™, Validated (per Product Data).
• What this typically implies (general context):
  • Recombinant: Sequence-defined production in a recombinant expression host (e.g., mammalian or microbial cells), enabling lot-to-lot consistency and elimination of hybridoma drift. No animal immunization required for production.
  • ExactAb™: Brand/line designation indicating controlled manufacturing and characterization workflows. Specific performance attributes under this mark are not specified for this item; refer to CoA/Spec Sheet.
  • Validated: Indicates the antibody has undergone internal testing against its intended antigen and/or in selected assay formats. Exact validated applications, species reactivity, and epitope mapping are not specified for this item.

Quality control considerations (general)

• Identity: Sequencing or peptide mapping of variable regions, intact mass analysis, and binding verification against B2R-derived antigen are commonly used.
• Purity: SDS-PAGE/CGE for HC/LC purity, size-exclusion chromatography for aggregates, residual host-cell protein/DNA testing for recombinant production.
• Functional assessment: Binding ELISA to immunogen, capture/detection in sandwich formats, or cell-based binding assays when targets are membrane proteins (e.g., GPCRs like B2R).
• Documentation: For item-specific release specs (protein concentration, endotoxin level, host/isotype, buffer composition, preservative/stabilizer), consult the CoA/Spec Sheet.

Practical tip

• Use the same lot for an entire study when possible; verify performance in your assay by a small pilot before full deployment.

Reaction and Applications

Scope of use (research only)

• Antibodies are used as affinity reagents in immunoassays and imaging, not as stoichiometric or catalytic reagents in chemical synthesis.

General applications for recombinant antibodies (literature; not item-specific claims)

• Western blot (WB): Detection of denatured target proteins in lysates. For GPCRs such as B2R, sample preparation (e.g., membrane fractions) and optimized SDS-PAGE conditions can enhance detection.
• Immunocytochemistry/Immunofluorescence (ICC/IF): Visualization of cellular localization; fixation/permeabilization must preserve epitope integrity. For cell surface GPCRs, live-cell labeling protocols may be applicable if the epitope is extracellular.
• Immunohistochemistry (IHC): Detection in tissue sections; antigen retrieval conditions (heat/enzymatic) require optimization.
• Flow cytometry (FC): Binding to extracellular epitopes on intact cells to quantify surface receptor expression.
• ELISA/ELISpot: Quantitative binding to immobilized antigen or capture/detection in sandwich formats.
• Immunoprecipitation (IP)/Co-IP: Enrichment of antigen complexes from lysates; detergent choice is critical for membrane proteins.

Practical considerations

• Titer optimization: Begin with a dilution series to define the dynamic range and minimize background.
• Controls: Include isotype and no-primary controls; where possible, use antigen competition or CRISPR/siRNA knockout lines for specificity assessment.
• For this SKU: Specific validated applications, host/isotype, clonality, and recommended dilutions are not specified. Refer to the CoA/Spec Sheet and perform assay-specific pilots.

Reaction Conditions

Not a chemical reagent; classical reaction conditions (solvent, temperature, catalysts) are not applicable.

Assay-condition guidance for antibodies (general)

• Temperature: Perform binding incubations at room temperature or 4°C depending on assay (e.g., 4°C for flow cytometry to minimize internalization; RT for many ELISA/WB steps).
• Time: Primary incubations range from 1 h at RT to overnight at 4°C. Optimize empirically to balance signal and background.
• Concentration: Start with a broad dilution series (e.g., 1:200 to 1:5,000 for unconjugated primaries in WB/ELISA) and refine. Exact recommended dilutions for this item are not specified.
• Buffers: Use isotonic PBS/TBS with appropriate blocking agents and mild detergents as needed. Validate antigen retrieval conditions for IHC.
• Materials compatibility: Use low-binding plastics and avoid freeze–thaw to maintain active concentration.

Documentation

• For this SKU, no item-specific tested conditions are provided. Consult the CoA/Spec Sheet and perform small-scale optimization in your specific assay system.

Safety and Handling

Item-specific hazard information

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS.
• Research use: For research use only (per Product Data).

General safety guidance for protein antibodies (literature/good practice)

• PPE: Wear lab coat, disposable nitrile gloves, and safety glasses. Handle in a clean area to avoid contamination.
• Inhalation/ingestion/skin contact: Avoid aerosol generation and direct contact. Wash thoroughly after handling. Do not pipette by mouth.
• Biological origin: Recombinant antibodies are produced in controlled expression systems; nonetheless treat as biological material. Follow your institution’s biosafety procedures.
• Incompatibilities: Avoid mixing with strong oxidizers or proteases. Avoid exposure to extreme pH (<5 or >9) or high shear, which can denature proteins.
• Special risks: Repeated freeze–thaw cycles can cause aggregation/precipitation and loss of binding activity.
• First-aid (overview; defer to SDS): In case of contact, rinse skin/eyes with water. If inhaled, move to fresh air. If swallowed, rinse mouth and seek medical advice if unwell. Show SDS to medical personnel.
• Spill/cleanup: Absorb aqueous spills with inert material, wash area with suitable cleaner. Dispose of waste according to institutional and local regulations.

Always consult the product’s SDS for authoritative safety, toxicological, and disposal information.

Solvent Selection

Applicability

• This product is an aqueous biological reagent (antibody). Selection focuses on buffer systems rather than organic solvents.

General buffer/solvent guidance for antibodies (literature)

• Preferred media: Isotonic, near-neutral buffers such as PBS (10–50 mM phosphate, 150 mM NaCl, pH 7.2–7.6) or TBS (Tris-buffered saline, pH 7.4–8.0). Low concentrations of nonionic surfactants (e.g., 0.01% Tween-20) can reduce nonspecific adsorption in assays but may influence binding in certain contexts.
• Additives: Stabilizers like trehalose or sucrose (2–5%) and carrier proteins (e.g., BSA) can improve freeze–thaw resilience; presence/amount for this item is not specified.
• Avoid: High percentages of organic solvents (acetone, acetonitrile, DMSO >10%), extreme pH, and chaotropes unless specifically required for a protocol (risk of denaturation).
• Detergents: For membrane-targets (e.g., GPCRs), mild detergents may be present in assay buffers to preserve antigen conformation in cell/tissue lysates. Optimize empirically.

Comparison (general)

• PBS vs TBS: PBS is widely compatible with most immunoassays; TBS can reduce background in alkaline phosphatase-based detection and in some IHC workflows. Choose based on downstream detection chemistry and sample.

Item-specific note

• The supplied buffer and any preservatives for this SKU are not specified; consult the CoA/Spec Sheet and adjust your assay buffers accordingly.

Storage and Reconstitution

Item-specific instructions (from Product Data)

• Storage conditions: Store at -20°C.
• Handling: Avoid repeated freezing and thawing.
• Shipping: Shipped in ice chest with ice pads.

Additional guidance (general; not item-specific specifications)

• Aliquoting: Upon first receipt, aliquot into single-use volumes to minimize freeze–thaw stress. Use low-protein-binding tubes.
• Short-term storage: Working aliquots may be kept at 2–8°C for brief periods during active use if preservative is present; duration depends on buffer composition (not specified for this item).
• Long-term storage: Many antibodies remain stable at -20°C to -80°C, especially with 10–50% glycerol or sugars; actual stabilizers for this SKU are not specified.
• Light and agitation: Protect from strong light and avoid vigorous vortexing to reduce aggregation and activity loss.
• Reconstitution: If supplied lyophilized (not specified), reconstitute with sterile, antibody-grade water or buffer as indicated on the label/CoA, gently invert to dissolve, and allow to equilibrate on ice. Record final concentration and date.

Documentation

• For definitive storage buffer composition, presence of preservatives/stabilizers, and reconstitution volume, consult the item label and CoA/Spec Sheet.

Structure and Identity

Item-specific identifiers (from Product Data)

• SKU: Ab090383
• Product name: Recombinant B2R Antibody
• Grade/Purity: Recombinant, ExactAb™, Validated
• CAS, InChIKey, SMILES, CID: Not applicable to antibodies; not specified for this item.
• Molecular formula / exact molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General structure notes (literature)

• Antibody class: Recombinant monoclonal antibody (isotype, clonality, and host species not specified for this item).
• Macromolecular architecture: Typical IgG antibodies are ~150 kDa heterotetramers with two identical heavy chains and two identical light chains linked by inter-chain disulfides; each arm contains a variable domain (VH/VL) forming the paratope that recognizes the antigen epitope.
• Post-translational modifications: Antibodies commonly exhibit N-linked glycosylation on the Fc domain; glycoform distribution depends on expression system (not specified for this item).
• Antigen target context: “B2R” generally denotes the bradykinin B2 receptor (BDKRB2), a class A GPCR localized at the plasma membrane. Exact immunogen/epitope information is not specified for this item; refer to CoA/Spec Sheet.

2D structural description (literature)

• Linear sequence comprises constant domains (CH1–CH3, CL) and variable domains with complementarity-determining regions (CDR1–3) shaping the antigen-binding site; Fc region mediates effector interactions (protein A/G binding, FcγR interactions). Stereochemistry is defined by protein secondary/tertiary folding rather than small-molecule chirality.

Synthetic Utility

Not typically applicable.

• As a protein affinity reagent, this antibody is not used as a building block or reagent in classical organic synthesis. It does not participate in named organic reactions, cross-couplings, or catalysis typical of small molecules.

Where it can intersect with “synthetic” workflows (general)

• Bio-conjugation: Antibodies can be chemically modified (e.g., NHS–ester labeling on lysines, maleimide–thiol coupling on engineered cysteines) to attach fluorophores, enzymes, or payloads for assay readouts. Any conjugation properties or formats for this SKU are not specified.
• Affinity purification: Antibodies immobilized on solid supports (e.g., Protein A/G capture, direct coupling to activated agarose) can serve in immunoaffinity chromatography to enrich target proteins from complex mixtures.

Item-specific caveat

• No conjugate, label, or immobilization chemistry is specified for this product. If conjugation is planned, verify buffer composition (amine-free for NHS chemistry) and perform small-scale pilots to preserve antigen-binding activity.

Target Specificity

Item-specific information

• Antigen/target, epitope, species reactivity, isotype/clone: Not specified for this item; refer to CoA/Spec Sheet.

General context (for clarity only)

• “B2R” typically refers to the bradykinin B2 receptor (BDKRB2), a class A GPCR. However, without item-specific data, no assertions can be made regarding this antibody’s epitope, cross-reactivity profile, or validated species/assays.